The Life Sciences team advised Orchard Therapeutics on the pricing of its initial public offering of 14,285,715 American Depositary Shares (“ADSs”) representing 14,285,715 ordinary shares at an initial public offering price of $14.00 per ADS, before underwriting discounts and commissions. In addition, Orchard has granted the underwriters a 30-day option to purchase up to an additional 2,142,857 ADSs at the initial public offering price, less the underwriting discounts and commissions.
The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Orchard, are expected to be $200 million, excluding any exercise of the underwriters’ option to purchase additional ADSs. The offering is expected to close on November 2, 2018, subject to the satisfaction of customary closing conditions.
Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies.
The cross-border, cross-disciplinary Goodwin team is led by partners Michael Bison and Andrew Harrow and includes partners Mitchell Bloom, Julie Tibbets, Daniel Karelitz, Sarah Bock, Duncan Greenhalgh, Jennifer Fay, Roger Cohen, and Ettore Santucci; counsel Brian Mukherjee; and associates Courtney Hetrick, Catherine Magazu, Carly Ward, Chris Huntsman, Steven Tjoe, Jonathan LaPlante, Caroline Galiatsos and Katie Leah.
For additional details on the offering, please read the press release.